Search results
Showing 1 to 15 of 110 results for paclitaxel
In development [GID-TA11340] Expected publication date: 21 May 2025
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
In development [GID-TA11461] Expected publication date: TBC
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable. This is because Celgene technology did not provide an evidence submission.
Show all sections
Sections for TA362
NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA560
NICE is unable to make a recommendation on atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA618
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
This guideline covers detecting, diagnosing and treating women (aged 18 and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.
Pancreatic cancer in adults: diagnosis and management (NG85)
This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.